ZYBERNO
Stock Report
Updated Aug 31, 2026

Alamar Biosciences, Inc. (ALMR)

NASDAQ

$30.71

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
Alamar Biosciences, Inc. (ALMR) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.27x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-18.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Alamar Biosciences, Inc. (ALMR) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:30.71
Market Cap:$1.80B

Valuation Multiples (2)

P/B Ratio:5.76x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.71B

Price Action & Momentum (1)

% of 52-Week High:79.7%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:5.6%
Fundamental Growth Rate (g):-1.0%

Margin Analysis (1)

Ebitda Margin:-42.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:11.85x
Quick Ratio:10.23x
Cash Ratio:4.76x

Leverage Analysis (3)

Debt To Equity Ttm:0.27x
Debt-to-Equity Ratio:0.27x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-241.64x
Times Interest Earned:-241.64

Capital Structure (4)

Working Capital:303,422,000.00
Cash And Cash Equivalents:132,969,000.00
Long Term Debt:$39.18M
Net Debt:-$91.51M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$117.71M
Cost Of Revenue Ttm:$46.84M

Profitability Breakdown (2)

$70.87M-$54.13M

Bottom Line Performance (3)

-$52.80M
Income Before Tax:-$13.29M
Ebitda Ttm:-49,460,000.00

Operating Expenses (5)

Operating Expenses:31,250,000.00
R And D Expense:13,817,000.00
Sga Expense:17,433,000.00
Income Tax Expense:-$93.00K
Interest Expense:224,000.00

Expense Ratios (3)

R And D To Revenue Percentage:47.0%
Sga To Revenue Percentage:59.2%
Ebitda Margin:-42.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$390.98M
Current Assets:$331.38M
Ppe Net:13,358,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:78,118,000.00
Current Liabilities:27,960,000.00
Long Term Debt:$39.18M
Short Term Debt:$2.28M

Equity & Capital (3)

Equity:$312.86M
Retained Earnings:-$203.30M
Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:20,344,000.00
Inventory:45,409,000.00
Accounts Payable:13,790,000.00

Special Items (2)

Contract Liabilities:2,400,000.00
Stock Based Compensation:3,280,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$81.39M-$83.79M

Investment Activities (1)

Investing Cash Flow:-$778.00K

Financing Activities (3)

Financing Cash Flow:$55.76M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.90

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.01
Operating Cash Flow Per Share:-$1.39

Book Value & Capital (2)

Book Value Per Share:$5.33
Cash Per Share:2.27

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.41x
Working Capital Turnover Ttm:0.39x

Receivables Management (2)

Receivables Turnover Ttm:5.79x
Days Sales Outstanding Ttm:63.08

Inventory Management (2)

Inventory Turnover Ttm:1.03x
Days Inventory Outstanding Ttm:353.88

Payables & Cash Cycle (2)

Days Payable Outstanding:107.47
Cash Conversion Cycle:309.50
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:5.6%
Fundamental Growth Rate (g):-1.0%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:ALMR
Company Name:Alamar Biosciences, Inc.
Sector:Unknown
Industry:Laboratory Analytical Instruments
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:58.67M
Shares Outstanding Basic:58.67M
Shares Outstanding Diluted:58.67M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 18:22:06 UTC
Data Timestamp:2026-08-31T18:22:06.319262
Scroll to Top